SMA with 3 copies SMN2 gene
Rare disease · 2023–2023
1decision
1medicine
1carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nusinersen Pre-symptomatic spinal muscular atrophy (SMA) with 3 copies of the survival of motor neuron 2 (SMN2) gene in patients aged less than 36 months. | Jul 2023 | Recommended with restriction | 1 individuals |
What the PBS pays
$55M in government benefit over 2024–25, across 530 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| nusinersen | $55.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.